Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.7 EUR | -0.45% | -4.39% | +2.17% |
07/03 | Neurones: 11% growth in annual net income | CF |
06/03 | Neurones S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company appears highly valued given the size of its balance sheet.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: IT Services & Consulting
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.17% | 1.16B | - | ||
-12.23% | 194B | A- | ||
+0.74% | 166B | B+ | ||
+2.19% | 153B | B- | ||
+4.34% | 99.85B | A- | ||
+7.04% | 77.56B | A- | ||
+19.09% | 73.55B | C- | ||
-7.30% | 71B | A | ||
-20.54% | 52.81B | C | ||
+0.53% | 47.86B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NRO Stock
- Ratings NEURONES